JP2006522062A5 - - Google Patents

Download PDF

Info

Publication number
JP2006522062A5
JP2006522062A5 JP2006504970A JP2006504970A JP2006522062A5 JP 2006522062 A5 JP2006522062 A5 JP 2006522062A5 JP 2006504970 A JP2006504970 A JP 2006504970A JP 2006504970 A JP2006504970 A JP 2006504970A JP 2006522062 A5 JP2006522062 A5 JP 2006522062A5
Authority
JP
Japan
Prior art keywords
methyl
dihydro
benzodiazepine
dioxolo
aminophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006504970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006522062A (ja
Filing date
Publication date
Priority claimed from GBGB0307860.7A external-priority patent/GB0307860D0/en
Application filed filed Critical
Publication of JP2006522062A publication Critical patent/JP2006522062A/ja
Publication of JP2006522062A5 publication Critical patent/JP2006522062A5/ja
Pending legal-status Critical Current

Links

JP2006504970A 2003-04-04 2004-04-02 神経学的障害の処置のための抗癲癇剤を含む組み合わせ Pending JP2006522062A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0307860.7A GB0307860D0 (en) 2003-04-04 2003-04-04 Organic compounds
PCT/EP2004/003518 WO2004087161A1 (en) 2003-04-04 2004-04-02 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders

Publications (2)

Publication Number Publication Date
JP2006522062A JP2006522062A (ja) 2006-09-28
JP2006522062A5 true JP2006522062A5 (cg-RX-API-DMAC7.html) 2007-05-17

Family

ID=9956223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006504970A Pending JP2006522062A (ja) 2003-04-04 2004-04-02 神経学的障害の処置のための抗癲癇剤を含む組み合わせ

Country Status (10)

Country Link
US (1) US20060194766A1 (cg-RX-API-DMAC7.html)
EP (1) EP1620103A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006522062A (cg-RX-API-DMAC7.html)
CN (1) CN100546581C (cg-RX-API-DMAC7.html)
AU (1) AU2004226825B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0409170A (cg-RX-API-DMAC7.html)
CA (1) CA2521274A1 (cg-RX-API-DMAC7.html)
GB (1) GB0307860D0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05010707A (cg-RX-API-DMAC7.html)
WO (1) WO2004087161A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US20100168174A1 (en) * 2007-07-13 2010-07-01 Eisai R&D Management Co., Ltd. Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain
WO2009015244A1 (en) * 2007-07-23 2009-01-29 Synosia Therapeutics Rufinamide for the treatment of post-traumatic stress disorder
ES2742728T3 (es) 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PT3856182T (pt) 2018-09-28 2026-03-10 Karuna Therapeutics Inc Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB864536A (en) * 1957-11-06 1961-04-06 Sapos S A Lab ª‡-ethyl-phenylacetylurea
GB1028234A (en) * 1964-01-06 1966-05-04 Ici Ltd New pharmaceutical compositions comprising 5-aminodibenzocycloheptene derivatives
WO1989005642A1 (en) * 1987-12-22 1989-06-29 Ferkany John W Dextrorphan potentiator for anticonvulsant composition and method
US5095033A (en) * 1991-03-01 1992-03-10 Laboratoires Biocodex Method for treating epilepsy
IT1261808B (it) * 1993-07-06 1996-06-03 Impiego di l-carnitina o acido l-carnitine e valproato nel trattamentodei disosrdini convulsivi
DE69724144D1 (de) * 1996-10-19 2003-09-18 Univ Wales Bangor Verfahren zur herstellung von chemisch reaktiver stärke
CZ141399A3 (cs) * 1996-10-24 1999-07-14 Novartis Ag Substituované aminoalkanfosfonové kyseliny, způsob jejich přípravy a farmaceutické prostředky, které je obsahují
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
CN1265889A (zh) * 1999-03-06 2000-09-13 王学勇 一种治疗癫痫病的药物
CA2392879C (en) * 1999-12-01 2005-03-29 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
IL161700A0 (en) * 2001-11-12 2004-09-27 Novartis Ag Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain

Similar Documents

Publication Publication Date Title
TWI762505B (zh) 細胞代謝過程之抑制劑
AU2011227398C1 (en) Modulators of Hec1 activity and methods therefor
JP2022536728A5 (cg-RX-API-DMAC7.html)
TWI500616B (zh) 新穎之雙環吡啶酮
CN111801339B (zh) 5-氟尿嘧啶化合物
JP2008500390A5 (cg-RX-API-DMAC7.html)
AR072688A1 (es) Nucleosidos y nucleotidos biciclicos como agentes terapeuticos
JP2003513015A5 (cg-RX-API-DMAC7.html)
EP4218935A1 (en) Lxrbeta agonist for the treatment of cancer
JP2019514950A5 (cg-RX-API-DMAC7.html)
JP2005504080A5 (cg-RX-API-DMAC7.html)
WO2008005956A3 (en) Pyrrolotriazine kinase inhibitors
JP2019014758A (ja) デオキシウリジントリホスファターゼ阻害剤
RU2006107785A (ru) 2, 4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
RU96111418A (ru) ПРОИЗВОДНЫЕ ПИРИМИДИНДИОНА, ПИРИМИДИНТРИОНА, ТРИАЗИНДИОНА, ТЕТРАГИДРОХИНАЗОЛИНДИОНА В КАЧЕСТВЕ АНТАГОНИСТОВ α1 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ
JP2004525149A5 (cg-RX-API-DMAC7.html)
NZ594332A (en) Compounds for the prevention and treatment of cardiovascular disease
JP2017528494A (ja) sGC刺激剤
JP2004527560A5 (cg-RX-API-DMAC7.html)
AU2017207291A1 (en) Methods for the treatment of myeloid derived suppressor cells related disorders
JP2016094432A (ja) キナーゼインヒビター、そのプロドラッグ型および治療におけるそれらの使用
JP7590351B2 (ja) Prmt5阻害剤を使用した癌の治療法
JP2024504632A (ja) 非アルコール性脂肪肝疾患および関連する疾患または障害を処置または改善するための化合物、組成物および方法
MA28583B1 (fr) Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale
CA2460135C (en) Use of pyridazinone compounds as phosphodiesterase iv inhibitors for treating cancer and other diseases